EpiciphAI: Reading disease states from blood’s epigenetic fingerprints

EpiciphAI is developing a liquid biopsy that reads histone marks on cell-free chromatin to identify a fragment’s tissue of origin and distinguish disease-associated states within that tissue. Still at the pre-seed stage, the company sees an initial application in diagnosing and monitoring cancers in tissues that are difficult to biopsy.

Most epigenetic liquid biopsies read methylation marks written directly on DNA; EpiciphAI instead reads chemical tags on histone proteins that package the DNA, which may capture additional information about chromatin state and tissue pathology...